Erratum: Medizinische Klinik (2007) 102, (631-646) DOI: 10.1007/s00063-007-1079-3));Doping in sport;Doping im sport

Medizinische Klinik

Volumn 102, Issue 8, 2007, Pages 631-646

  Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Adverse analytical findings; Doping analysis; Prohibited list; Side effects

Indexed keywords

AMFEPRAMONE; AMIPHENAZOLE; AMPHETAMINE; BEMEGRIDE; BENZPHETAMINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BOLDENONE; COCAINE; DEXTROMORAMIDE; DIMETAMFETAMINE; DIPIPANONE; GLUCOCORTICOID; ILLICIT DRUG; METANDIENONE; METENOLONE; METHADONE; METHAMPHETAMINE; METHYLPHENIDATE; MORPHINE; N ETHYLAMPHETAMINE; NANDROLONE; NORPSEUDOEPHEDRINE; PENTETRAZOLE; PETHIDINE; PHENDIMETRAZINE; PHENMETRAZINE; PROLINTANE; STANOZOLOL; TESTOSTERONE; UNINDEXED DRUG;

ANALYTIC METHOD; DOPING; DRUG EFFECT; DRUG MARKETING; DRUG SCREENING; HUMAN; REVIEW; SPORT; STATISTICS; SUBSTANCE ABUSE;

EID: 34548400868     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-007-1099-z     Document Type: Erratum

References (48)

1. Donike M. Doping. In: Trainerakademie Köln e.V., Hrsg. Studienbrief 10 der Trainerakademie Köln. Schorndorf: Hoffmann, 1990:185-216.
2. Franke WW, Berendonk B. Hormonal doping and androgenization of athletes: a secret program of the German Democratic Republic government. Clin Chem 1997;43:1262-79.
3. Striegel H, Simon P, Frisch S, et al. Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend 2006;81:11-9.
4. POL-GOE. Große Mengen Anabolika bei Festnahmen sichergestellt (463/2007). 2007 (http://www.presseportal.de/polizeipresse/p_story.htx?nr= 968995& firmaid=7452&keygroup=bild, 7. 5. 2007).
5. Kindermann W. Kardiovaskuläre Nebenwirkungen von anabol-androgenen Steroiden. Herz 2006;31:566-73.
6. Yesalis CE, Bahrke MS. Anabolic-androgenic steroids. Current issues. Sports Med 1995;19:326-40.
7. Soe KL, Soe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992;12:73-9.
8. Smith DA, Perry PJ. The efficacy of ergogenic agents in athletic competition. Part I: Androgenic-anabolic steroids. Ann Pharmacother 1992;26:520-8.
9. Rockhold RW. Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 1993;33:497-520.
10. O'Sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic-androgenic steroids: medical assessment of present, past and potential users. Med J Aust 2000;173:323-7.
11. Dickerman RD, McConathy WJ, Schaller F, et al. Cardiovascular complications and anabolic steroids. Eur Heart J 1996;17:1912.
12. Dickerman RD, Schaller F, Prather I, et al. Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 1995;86:172-3.
13. Fineschi V, Riezzo I, Centini F, et al. Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med 2007;121:48-53.
14. Fineschi V, Baroldi G, Monciotti F, et al. Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med 2001;125:253-5.
15. Deligiannis A, Bjornstad H, Carre F, et al. ESC Study Group of Sports Cardiology position paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil 2006;13:687-94.
16. Tagarakis CVM, Bloch W, Hartmann G, et al. Anabolic steroids inhibit the exercise-induced increase of the capillarisation of the heart. Eur Heart J 1995;16:312.
17. Kley HK. Leistungsbeeinflussung durch Peptidhormone: Wachstumshormon, ein anaboles Dopingmittel? Dtsch Z Sportmed 1985;4:113-8.
18. Jung F, Scherges M, Fürst P. Illegale und gefälschte Wachstumshormonpräparate. Dtsch Apoth Ztg 2002;142:50-61.
19. Sonksen PH. Hormones and sport (insulin, growth hormone and sport). J Endocrinol 2001;170:13-25.
20. Jelkmann W. Erythropoietin. J Endocrinol Invest 2003;26:832-7.
21. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004;43:649-59.
22. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power. Scand J Med Sci Sports 1991;1:88-93.
23. Schäfer EA. The endocrine organs: an introduction to the study of internal secretion. London: Longmans Green, 1916.
24. IDF. Diabetes epidemic out of control. Brüssel: IDF, 2006 (http://www.idf.org/home/index.cfm?unode=7F 22F450-B1ED-43BB-A57C- B975D16A812D, 30. 4. 2007).
25. Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47-51.
26. Wolfe RR. Effects of insulin on muscle tissue. Curr Opin Clin Nutr Metab Care 2000;3:67-71.
27. Wolfe RR. Regulation of skeletal muscle protein metabolism in catabolic states. Curr Opin Clin Nutr Metab Care 2005;8:61-5.
28. Steiner A, Wagner RA. Insulin. Arnsberg: ISP, 2002:4-73.
29. Dawson RT, Harrison MW. Use of insulin as an anabolic agent. Br J Sports Med 1997;31:259.
30. Evans PJ, Lynch RM. Insulin as a drug of abuse in body building. Br J Sports Med 2003;37:356-7.
31. Rich JD, Dickinson BP, Merriman NA, et al. Insulin use by bodybuilders. JAMA 1998;279:1613.
32. Young J, Anwar A. Strong diabetes. Br J Sports Med 2007;41:335-6, discussion 36.
33. Hacke D, Ludwig U, Pfeil G, et al. Inside the blood doping investigation. 2006 (http://www.spiegel.de/international/spiegel/0,1518,425939,00.html, 17. 4. 2007).
34. Reverter JL, Tural C, Rosell A, et al. Self-induced insulin hypoglycemia in a bodybuilder. Arch Intern Med 1994;154:225-6.
35. Parsons JP, Mastronarde JG. Exercise-induced bronchoconstriction in athletes. Chest 2005;128:3966-74.
36. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med 2005;353:2637-9.
37. Forth W, Henschler D, Riummel W, et al. Allgemeine und spezielle Pharmakologie und Toxikologie. Heidelberg-Berlin: Spektrum Akademischer Verlag, 1996.
38. De Mondenard JP. Dictionnaire du dopage: substance, procédé s, conduites, dangers. Paris: Masson, 2004.
39. Thevis M, Schänzer W. Identification and characterization of peptides and proteins in doping control analysis. Curr Proteomics 2005;2:191-208.
40. Schumacher YO, Ashenden M. Doping with artificial oxygen carriers: an update. Sports Med 2004;34:141-50.
41. Schumacher YO, Schmid A, Dinkelmann S, et al. Artificial oxygen carriers - the new doping threat in endurance sport? Int J Sports Med 2001;22:566-71.
42. Mathurin JC, de Ceaurriz J, Audran M, et al. Detection of perfluorocarbons in blood by headspace solid-phase microextraction combined with gas chromatography/mass spectrometry. Biomed Chromatogr 2001;15:443-51.
43. Wu AH, Bristol B, Sexton K, et al. Adulteration of urine by "Urine Luck". Clin Chem 1999;45:1051-7.
44. Thevis M, Maurer J, Kohler M, et al. Proteases in doping control analysis. Int J Sports Med 2007;28:545-9.
45. Thevis M, Geyer H, Mareck U, et al. Detection of manipulation in doping control urine sample collection: a multidisciplinary approach to determine identical urine samples. Anal Bioanal Chem 2007;388:1351-8.
46. Sweeney H. Gene doping. Sci Am 2004;291:62-9.
47. Haisma HJ, de Hon O. Gene doping. Int J Sports Med 2006;27:257-66.
48. Lasne F, Martin L, de Ceaurriz J, et al. "Genetic doping" with erythropoietin cDNA in primate muscle is detectable. Mol Ther 2004;10:409-10.